Table 2.

Polymorphisms associated with P values < 0.01 in the SNP500Cancer-Illumina OPA and risk of colorectal cancer in the NHS and HPFS

dbSNP IDSNP500 Cancer ID
Nucleotide position*Cases, n (%)Controls, n (%)Conditional OR (95% CI)Multivariate OR (95% CI)
Alleles§
rs8177426GPX3 28**IVS1-1961A>G
GG249 (71.8)215 (62.9)1.01.0
GA98 (28.2)125 (36.5)0.66 (0.48-0.91)0.69 (0.48-0.98)
AA0 (0)2 (0.6)
Ptrend0.02
GA + AA981270.66 (0.48-0.90)0.68 (0.48-0.97)
rs8177447GPX3 16IVS4-14 T>C
CC260 (72.6)224 (62.8)1.01.0
CT89 (24.9)116 (32.5)0.69 (0.50-0.94)0.73 (0.51-1.04)
TT9 (2.5)17 (4.8)0.47 (0.20-1.10)0.43 (0.17-1.08)
Ptrend0.03
CT + TT981330.65 (0.49-0.89)0.69 (0.49-0.97)
rs707889HFE 08IVS6 + 462G>A
CC231 (65.3)195 (54.8)1.01.0
CT116 (32.8)138 (38.8)0.69 (0.49-0.97)0.60 (0.41-0.87)
TT7 (2.0)23 (6.5)0.28 (0.11-0.71)0.22 (0.08-0.60)
Ptrend0.0002
CT + TT1231610.63 (0.46-0.87)0.54 (0.38-0.78)
rs3093546LTA 05Ex1 + 50A>G
CC332 (95.4)311 (89.4)1.01.0
CT15 (4.3)36 (10.34)0.38 (0.20-0.72)0.38 (0.19-0.76)
TT1 (0.29)1 (0.29)
Ptrend0.02
CT + TT16370.40 (0.22-0.74)0.40 (0.21-0.79)
rs6463524PMS2 11S260S; Ex7-24G>C
GG221 (61.9)253 (70.9)1.01.0
GC119 (33.3)95 (26.6)1.51 (1.07-2.13)1.54 (1.06-2.24)
CC17 (4.76)9 (2.52)2.30 (1.00-5.27)2.34 (0.95-5.79)
Ptrend0.008
GC + CC1361041.57 (1.12-2.20)1.60 (1.11-2.30)
rs3731239CDKN2A 12IVS2 + 185C>T
AA153 (42.7)119 (33.3)1.01.0
AG161 (45.0)176 (49.3)0.72 (0.52-0.99)0.72 (0.51-1.01)
GG44 (12.3)62 (17.4)0.55 (0.35-0.87)0.54 (0.33-0.90)
Ptrend0.01
AG + GG2052380.68 (0.50-0.92)0.68 (0.49-0.94)
rs2308327MGMT 03Lys178Arg; Ex4 + 119A>G
AA303 (85.1)266 (74.7)1.01.0
AG52 (14.6)84 (23.6)0.54 (0.37-0.79)0.55 (0.36-0.82)
GG1 (0.28)6 (1.7)
Ptrend0.001
AG + GG53900.51 (0.35-0.75)0.52 (0.35-0.78)
rs2288729APAF1 04IVS12 + 2093G>A
AA193 (54.1)164 (45.9)1.01.0
AG144 (40.3)158 (44.3)0.75 (0.55-1.04)0.76 (0.54-1.08)
GG20 (5.6)35 (9.8)0.46 (0.25-0.85)0.46 (0.24-0.91)
Ptrend0.02
AG + GG1641930.70 (0.51-0.96)0.71 (0.51-1.00)
rs2412546RAD51 16IVS5-4480G>A
AA75 (21.0)102 (28.6)1.01.0
AG187 (52.2)179 (50.1)1.41 (0.98-2.02)1.49 (1.00-2.21)
GG96 (26.8)76 (21.3)1.73 (1.12-2.66)2.01 (1.24-3.25)
Ptrend0.004
AG + GG2832551.50 (1.06-2.12)1.62 (1.11-2.37)
rs28566535CYP19A1 30IVS2 + 14872T>G
AA307 (85.8)328 (91.9)1.01.0
AC47 (13.1)28 (7.8)1.73 (1.07-2.81)1.64 (0.96-2.82)
CC4 (1.12)1 (0.28)
Ptrend0.01
AA + CC51291.82 (1.13-2.93)1.84 (1.09-3.09)
rs13894SAT2 01R126C; Ex6 + 31C>T
GG297 (83.2)320 (89.9)1.01.0
GA58 (16.3)36 (10.1)1.89 (1.19-3.01)2.47 (1.46-4.17)
AA2 (0.56)0 (0)
Ptrend0.0003
GA + AA60 (16.9)36 (10.1)1.93 (1.21-3.07)2.54 (1.50-4.29)
  • NOTE: The number of cases and controls do not add to the total number of study participants because individuals with missing exposure data were excluded from the analysis.

  • * For additional information on the nomenclature for description of the sequence variants, please see the SNP500Cancer database.

  • Conditional logistic regression conditioned on the strata are defined by the matching variables.

  • Conditional logistic regression conditioned on the strata are defined by the matching variables and adjusted for family history of colon cancer, pack-years of smoking, body mass index, postmenopausal hormone use, aspirin intake, physical activity, alcohol intake, dietary folate consumption, and red-meat consumption.

  • § Allele names are based on Illumina assay.

  • P value for the Armitage trend test.